Acute myeloid leukemia (AML) is the most common form of leukemia affecting the blood and bone marrow, and has been responsible for 1.8% of cancer deaths in 2016. Because it is so prevalent, many research teams around the world study this disease in search of new treatment methods. One of these research teams, from Harvard University, has joined up with the pharmaceutical company Merck in a $20 million collaboration to develop new therapeutics for leukemia.
0 Comments Click here to read/write comments
Tags: Harvard University, Northeast, Leukemia, cancer research, Massachusetts, Boston, BioResearch Product Faire Event, MA, Harvard, longwood, 2016, cancer therapy, Merck